Aspira Women’s Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
11 Março 2024 - 9:00AM
Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq:
AWH), a bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced that the Company will report its financial results for
the three months and year ended December 31, 2023 on Thursday,
March 28, 2024. Management will also host a conference call at 4:30
pm to discuss financial results and provide a corporate update.
Details for the call are as follows:
Conference Call & Webcast Details:
Date: |
Thursday, March 28, 2024 |
Time: |
4:30 pm |
Toll Free: |
877-407-4018 |
International: |
201-689-8471 |
Webcast: |
Click HERE |
Call MeTM: |
Click HERE |
|
|
Participants can use the Guest dial-in numbers above and be
answered by an operator OR participants can click the Call Me link
for instant telephone access to the event. The Call Me link will be
made active 15 minutes prior to the scheduled start time.
A replay of the webcast will also be available on the Events
& Presentation page of the Aspira Women’s Health Investor
Relations website.
About Aspira Women’s Health Inc.Aspira Women’s
Health Inc. is dedicated to the discovery, development, and
commercialization of noninvasive, AI-powered tests to aid in the
diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM.
Together, they provide the only comprehensive portfolio of blood
tests to aid in the detection of ovarian cancer for the 1.2+
million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of 99% and is used to
assess ovarian cancer risk for women where initial clinical
assessment indicates the mass is indeterminate or benign, and thus
surgery may be premature or unnecessary. Ova1Plus is comprised of
two FDA-cleared tests, Ova1® and Overa®, to assess the risk of
ovarian malignancy in women planned for
surgery.
Our in-development test pipeline is designed to expand our
ovarian cancer portfolio and addresses the tremendous need for
noninvasive diagnostics for endometriosis, a debilitating disease
that impacts millions of women worldwide. In ovarian cancer, our
OvaMDxSM risk assessment is designed to combine microRNA and
protein biomarkers with patient data to further enhance the
sensitivity and specificity of our current tests. In endometriosis,
EndoCheckSM is the first-ever noninvasive test designed to identify
endometriomas, one of the most commonly occurring forms of
endometriosis. The EndoMDxSM test is designed to combine microRNA
and protein biomarkers with patient data to identify all
endometriosis.
Forward-Looking Statements This press release
may contain forward-looking statements that are made pursuant to
the safe harbor provisions of the federal securities laws,
including those relating to the timing and completion of any
products in the pipeline development and other statement that are
predictive in nature. Actual results could differ materially from
those discussed due to known and unknown risks, uncertainties, and
other factors. These forward-looking statements generally can be
identified by the use of words such as “designed to,” “expect,”
“plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,”
“future,” other words of similar meaning and the use of future
dates. Forward-looking statements in this press release and other
factors that may cause such differences include the satisfaction of
customary closing conditions related to the offering and the
expected timing of the closing of the offering. These and
additional risks and uncertainties are described more fully in the
company’s filings with the SEC, including those factors identified
as “risk factors” in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q. We are providing this
information as of the date of this press release and do not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise, except as required by law.
Investor Relations Contact: Torsten
Hombeck, Ph.D. Chief Financial Officer Aspira Women’s
HealthInvestors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024